Alhayki Maryam, Hopkins Laura, Le Tien
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology University of Ottawa, Ottawa, Canada.
Obstet Gynecol Surv. 2006 Aug;61(8):529-34. doi: 10.1097/01.ogx.0000228777.15365.32.
A large, recent study has shown significantly improved survival in women with epithelial ovarian cancer treated with intraperitoneal chemotherapy. This review is intended for all clinicians caring for women with ovarian cancer, including family physicians, general gynecologists, and oncologists. The subset of patients most likely to derive a survival benefit from intraperitoneal chemotherapy should be distinguished. Because effective surgical debulking is critical to long-term survival for ovarian cancer, it is important that women known or suspected to have ovarian cancer should be referred to centers with the surgical expertise and resources necessary for aggressive tumor debulking and safe delivery of intraperitoneal chemotherapy.
Obstetricians & Gynecologists, Family Physicians.
After completion of this article, the reader should be able to state that there is a subset of women with widespread intraabdominal ovarian cancer who will have improved survival after a debulking procedure and intraperitoneal (IP) chemotherapy and explain that there needs to be the expertise and resources necessary to follow these patients.
近期一项大型研究表明，接受腹腔化疗的上皮性卵巢癌女性患者生存率显著提高。本综述面向所有护理卵巢癌女性患者的临床医生，包括家庭医生、普通妇科医生和肿瘤学家。应区分出最有可能从腹腔化疗中获得生存益处的患者亚组。由于有效的肿瘤细胞减灭术对卵巢癌的长期生存至关重要，因此，对于已知或疑似患有卵巢癌的女性，应将其转诊至具备积极肿瘤细胞减灭术及安全实施腹腔化疗所需手术专业知识和资源的中心，这一点很重要。
妇产科医生、家庭医生。
阅读本文后，读者应能够指出，有一部分广泛腹腔内播散的卵巢癌女性患者，在接受肿瘤细胞减灭术和腹腔（IP）化疗后生存率会提高，并解释需要具备随访这些患者所需的专业知识和资源。
